{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:38:48Z","timestamp":1787009928023,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Mutations in the isocitrate dehydrogenase 1 (\n                      <jats:italic toggle=\"yes\">IDH1<\/jats:italic>\n                      ) and\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      genes are important for both the integrated diagnosis and the prognosis of diffuse gliomas. The p.R132H mutation of\n                      <jats:italic toggle=\"yes\">IDH1<\/jats:italic>\n                      is the most frequently observed\n                      <jats:italic toggle=\"yes\">IDH<\/jats:italic>\n                      mutation, while\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      mutations were relatively rarely studied. The aim of the study was to determine the pathological and genetic characteristics of lower-grade gliomas that carry\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Data from 238 adult patients with lower-grade gliomas were retrospectively analyzed. The status of\n                      <jats:italic toggle=\"yes\">IDH1<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      gene mutations, telomerase reverse transcriptase (\n                      <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                      ) promoter mutations, O\n                      <jats:sup>6<\/jats:sup>\n                      -methylguanine-DNA-methyltransferase (\n                      <jats:italic toggle=\"yes\">MGMT<\/jats:italic>\n                      ) promoter methylation, 1p\/19q co-deletion and the expressions of IDH1 R132H, alpha-thalassemia X-linked mental retardation, and p53 were evaluated. Progression-free survival (PFS) and overall survival (OS) were calculated via Kaplan-Meier estimation using the log-rank test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Totally, 71% (169\/238) of patients were positive for\n                      <jats:italic toggle=\"yes\">IDH<\/jats:italic>\n                      mutations, including 12 patients harboring mutations in\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      . Among the 12 patients with\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      mutations, ten patients harbored the R172K mutation, one patient harbored the R172S mutation and one harbored the R172W mutation. Of these, 11 tumors occurred in the frontal lobe and showed morphology typical of oligodendroglioma. The proportion of grade II tumors was higher than that of grade III tumors in\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      mutant-gliomas.\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      mutations were frequently associated with\n                      <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                      promoter mutations, 1p\/19q co-deletion and\n                      <jats:italic toggle=\"yes\">MGMT<\/jats:italic>\n                      promoter methylation.\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      mutations were associated with better outcomes compared with\n                      <jats:italic toggle=\"yes\">IDH<\/jats:italic>\n                      wild-type gliomas (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.05). However, the PFS and OS did not differ from that of\n                      <jats:italic toggle=\"yes\">IDH1<\/jats:italic>\n                      mutant patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.95 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.60, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      mutations are more frequent in oligodendrogliomas and associated with a better prognosis.\n                      <jats:italic toggle=\"yes\">IDH2<\/jats:italic>\n                      mutations may segregate in distinct clinico-pathological and genetic subtypes of gliomas, and therefore may merit routine investigation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000000565","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T11:37:40Z","timestamp":1576150660000},"page":"2920-2926","source":"Crossref","is-referenced-by-count":10,"title":["Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas"],"prefix":"10.1097","volume":"132","author":[{"given":"Lei-Ming","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pathology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Shan","family":"Piao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ning","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China"},{"name":"National Clinical Research Centre for Geriatric Disorders, Beijing 100053, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Jing","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"R1-20230813","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathological"},{"key":"R2-20230813","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","article-title":"IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas","volume":"129","author":"Olar","year":"2015","journal-title":"Acta Neuropathological"},{"key":"R3-20230813","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.mam.2015.05.002","article-title":"Biomarker-driven diagnosis of diffuse gliomas","volume":"45","author":"Appin","year":"2015","journal-title":"Mol Aspects Med"},{"key":"R4-20230813","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20230813","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11060-017-2571-0","article-title":"Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria","volume":"135","author":"Visani","year":"2017","journal-title":"J Neurooncol"},{"key":"R6-20230813","doi-asserted-by":"crossref","first-page":"E1186","DOI":"10.1002\/humu.21201","article-title":"Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma","volume":"31","author":"Gravendeel","year":"2010","journal-title":"Hum Mutat"},{"key":"R7-20230813","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world's knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"R8-20230813","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.humpath.2018.04.015","article-title":"H3 K27M-mutant diffuse midline gliomas in different anatomical locations","volume":"78","author":"Wang","year":"2018","journal-title":"Hum Pathol"},{"key":"R9-20230813","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/jclinpath-2017-204620","article-title":"Gliosarcomas with the BRAF V600E mutation: a report of two cases and review of the literature","volume":"70","author":"Wang","year":"2017","journal-title":"J Clin Pathol"},{"key":"R10-20230813","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.prp.2017.10.007","article-title":"Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas","volume":"213","author":"Wang","year":"2017","journal-title":"Pathol Res Pract"},{"key":"R11-20230813","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.celrep.2018.03.133","article-title":"Mutant IDH1 promotes glioma formation in vivo","volume":"23","author":"Philip","year":"2018","journal-title":"Cell Rep"},{"key":"R12-20230813","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann Oncol"},{"key":"R13-20230813","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13046-016-0362-7","article-title":"The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas","volume":"35","author":"Wang","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"R14-20230813","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1074\/jbc.M112.435495","article-title":"The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization","volume":"288","author":"Ward","year":"2013","journal-title":"J Biol Chem"},{"key":"R15-20230813","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","article-title":"Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas","volume":"118","author":"Hartmann","year":"2009","journal-title":"Acta Neuropathol"},{"key":"R16-20230813","first-page":"716","article-title":"IDH2 mutations are commonly associated with 1p\/19q codeletion in diffuse adult gliomas","volume":"20","author":"Appay","year":"2018","journal-title":"Neuro Oncol"},{"key":"R17-20230813","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.humpath.2017.05.005","article-title":"Molecular classification of adult diffuse gliomas: conflicting IDH1\/IDH2, ATRX, and 1p\/19q results","volume":"69","author":"Ballester","year":"2017","journal-title":"Hum Pathol"},{"key":"R18-20230813","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"key":"R19-20230813","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.18632\/oncotarget.1765","article-title":"Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas","volume":"5","author":"Killela","year":"2014","journal-title":"Oncotarget"},{"key":"R20-20230813","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/modpathol.2014.94","article-title":"TERT promoter mutations contribute to subset prognostication of lower-grade gliomas","volume":"28","author":"Chan","year":"2015","journal-title":"Mod Pathol"},{"key":"R21-20230813","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40478-016-0351-2","article-title":"A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas","volume":"4","author":"Arita","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"R22-20230813","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/neuonc\/nos317","article-title":"IDH\/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival","volume":"15","author":"Leu","year":"2013","journal-title":"Neuro Oncol"},{"key":"R23-20230813","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/neuonc\/noy146","article-title":"Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide","volume":"21","author":"Yamashita","year":"2019","journal-title":"Neuro Oncol"},{"key":"R24-20230813","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.canlet.2016.01.024","article-title":"CGCG clinical practice guidelines for the management of adult diffuse gliomas","volume":"375","author":"Jiang","year":"2016","journal-title":"Cancer Lett"},{"key":"R25-20230813","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/neuonc\/nox054","article-title":"Correlation of immune phenotype with IDH mutation in diffuse glioma","volume":"19","author":"Berghoff","year":"2017","journal-title":"Neuro Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000000565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T04:18:09Z","timestamp":1691900289000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":25,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000000565","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]}}}